SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol

BACKGROUND: Sodium valproate (VPA) has been associated with a reduced risk of head and neck cancer development. The potential protective mechanism of action is believed to be via inhibition of histone deacetylase and subsequent epigenetic reprogramming. SAVER is a phase IIb open-label, randomised co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: McCarthy, Caroline, Sacco, Joseph, Fedele, Stefano, Ho, Michael, Porter, Stephen, Liloglou, Triantafillos, Greenhalf, Bill, Robinson, Max, Young, Bridget, Cicconi, Silvia, Chauhan, Seema, Tesfaye, Binyam, Jackson, Richard, Sherratt, Frances, Shaw, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8256209/
https://ncbi.nlm.nih.gov/pubmed/34225765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-021-05373-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados